Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.

Johnston, Stephen; O'Shaughnessy, Joyce; Martin, Miguel; Huober, Jens; Toi, Masakazu; Sohn, Joohyuk; André, Valérie A M; Martin, Holly R; Hardebeck, Molly C; Goetz, Matthew P

Johnston, Stephen; O'Shaughnessy, Joyce; Martin, Miguel; Huober, Jens; Toi, Masakazu; Sohn, Joohyuk; André, Valérie A M; Martin, Holly R; Hardebeck, Molly C; Goetz, Matthew P.

Afiliación

Johnston S; Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK. stephen.johnston@rmh.nhs.uk.
O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
Martin M; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Huober J; University of Ulm, Ulm, Germany.
Toi M; Breast Cancer Unit, Kyoto University Hospital, Kyoto University, Kyoto, Japan.
Sohn J; Yonsei Cancer Center, Seoul, South Korea.
André VAM; Eli Lilly and Company, Paris, France.
Martin HR; Eli Lilly and Company, Indianapolis, IN, USA.
Hardebeck MC; Eli Lilly and Company, Indianapolis, IN, USA.
Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, USA.

NPJ Breast Cancer ; 7(1): 80, 2021 Jun 22.

Article en En | MEDLINE | ID: mdl-34158513

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article